Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity

  • Emine Alyamaç SukgenEmail author
  • Yusuf Koçluk
Retinal Disorders



To compare the results of ranibizumab and aflibercept treatment in infants with treatment-requiring retinopathy of prematurity (ROP) in the posterior zone.


In this single-center, retrospective study, the records of the infants, who were treated between January 2015 and June 2017 in a tertiary center for screening and treatment of ROP, were reviewed. Infants who were administered ranibizumab or aflibercept as initial treatment and completed at least 1 year of corrected age were included. The patients were evaluated in terms of regression, progression or recurrence of the disease, vascularization of the peripheral retina, and ocular complication profile in early or late period.


Fifty-four eyes of 27 infants who received ranibizumab treatment (ranibizumab group) and 72 eyes of 36 infants who received aflibercept treatment (aflibercept group) were enrolled. The rate of recurrence was 48.1% in ranibizumab group and 13.9% in aflibercept group. The mean recurrence times were at 8.2 ± 0.92 weeks following the injection of ranibizumab and at 14.2 ± 1.03 weeks following the injection of aflibercept. There were significant statistical differences between the groups in the rate of ROP recurrence, the time of recurrence, and the time of vascularization of peripheral retina (p = 0.001, p < 0.001, p < 0.001, respectively).


Although both ranibizumab and aflibercept are effective therapies for the treatment of ROP, more frequent and much earlier recurrences can be seen with ranibizumab treatment. Further studies are needed to obtain ideal options for the treatment of ROP.


Retinopathy of prematurity Intravitreal Anti-VEGF Ranibizumab Aflibercept 


Compliance with ethical standards

The study was approved by the Ethics Committee of the Hospital and complied with the tenets of the Declaration of Helsinki. Informed consent was obtained from the parents of all patients.

The authors did not receive any financial support from any public or private sources.

The authors have no financial or proprietary interest in any product, method or material described herein.

Conflict of interest

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge, or beliefs) in the subject matter or materials discussed in this manuscript.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study. The authors did not receive any financial support from any public or private sources. The authors have no financial or proprietary interest in a product, method, or material described herein.


  1. 1.
    Gilbert C, Muhit M (2008) Twenty years of childhood blindness: what have we learned? Community eye health / International Centre for Eye Health 21(67):46–47Google Scholar
  2. 2.
    Blencowe H, Lawn JE, Vazquez T, et al. (2010) Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for. PediatrRes 2013;74 Suppl 1:35–49Google Scholar
  3. 3.
    Good WV, Early Treatment for Retinopathy of Prematurity Cooperative group (2004) Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc 102:233–248Google Scholar
  4. 4.
    Zhang G, Yang M, Zeng J et al (2016) Shenzhen Screening for Retinopathy of Prematurity Cooperative group. Comparison of intravitreal injection of Ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity. Retina 37(4):710–717CrossRefGoogle Scholar
  5. 5.
    Mintz-Hittner HA, Kennedy KA, Chuang AZ (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364:603–615CrossRefGoogle Scholar
  6. 6.
    Yetik H, Gunay M, Sirop S, Salihoglu Z (2014) Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27-month follow-up results from Turkey. Graefes Arch Clin Exp Ophthalmol 14:334–339Google Scholar
  7. 7.
    The section on Ophthalmology, American Academy of Pediatrics; American Academy of Ophthalmology (2013) American Association for Pediatric Ophthalmology and Strabismus. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 131:189–195CrossRefGoogle Scholar
  8. 8.
    Martin DF, Maguire MG, Ying GS et al (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897–1908CrossRefGoogle Scholar
  9. 9.
    International Committee for the Classification of Retinopathy of prematurity (2005) The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 123:991–999CrossRefGoogle Scholar
  10. 10.
    Salman AG, Said AM (2015) Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethresholdtype 1 retinopathy of prematurity. Ophthalmic Res 53(1):15–20. CrossRefGoogle Scholar
  11. 11.
    Alyamac Sukgen E, Çömez A, Koçluk Y, Cevher S (2016) The process of retinal vascularization after anti-VEGF treatment in retinopathy of prematurity:a comparison between Ranibizumab and bevacizumab. Ophthalmologica 236(3):139–147CrossRefGoogle Scholar
  12. 12.
    Avery RL, Castellarin AA, Steinle NC et al (2014) Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol 98:1636–1641CrossRefGoogle Scholar
  13. 13.
    Wu WC, Shih CP, Lien R, Wang NK et al (2017) Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity. Retina 37(4):694–701CrossRefGoogle Scholar
  14. 14.
    Ferrara N, Damico L, Shams N et al (2006) Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26:859–870CrossRefGoogle Scholar
  15. 15.
    Erol MK, Coban DT, Sari ES et al (2015) Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity. Arq Bras Oftalmol 78:340–343Google Scholar
  16. 16.
    Zehetner C, Kralinger MT, Modi YS et al (2015) Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomized, prospective trial. Acta Ophthalmol 93:e154–e159CrossRefGoogle Scholar
  17. 17.
    Papadopoulos N, Martin J, Ruan Q et al (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab, and bevacizumab. Angiogenesis 15:171–185CrossRefGoogle Scholar
  18. 18.
    Yi Z, Su Y, Zhou Y et al (2016) Effects of intravitreal Ranibizumab in the treatment of retinopathy of prematurity in Chinese infants. Curr Eye Res 41(8):1092–1097CrossRefGoogle Scholar
  19. 19.
    Stewart MW, Rosenfeld PJ, Penha FM et al (2012) Pharmacokinetic rationale for dosing every2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept(vascular endothelial growth factor trapeze). Retina 32:434–457Google Scholar
  20. 20.
    Hartnett ME (2014) Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity. Clin Perinatol 41:925–943CrossRefGoogle Scholar
  21. 21.
    Warden SM, Andreoli CM, Mukai S (2007) The Wnt signaling pathway in familial exudative vitreoretinopathy and Norrie disease. Semin Ophthalmol 22:211–217CrossRefGoogle Scholar
  22. 22.
    Sondell M, Lundborg G, Kanje M (1999) Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neurosci 19:5731–5740CrossRefGoogle Scholar
  23. 23.
    Jin KL, Mao XO, Greenberg DA (2000) Vascular endothelial growth factor: direct neuroprotective effect in vitro ischemia. ProcNatl Acad Sci USA 97:10242–10247CrossRefGoogle Scholar
  24. 24.
    Saint-Geniez M, Maharaj AS, Walshe TE et al (2008) Endogenous VEGF is required for visual function: evidence for a survival role on Müller cells and photoreceptors. PLoS One 3(11):e3554CrossRefGoogle Scholar
  25. 25.
    Zhou Y, Jiang Y, Bai Y et al (2015) Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab. Graefes Arch Clin Exp Ophthalmol.
  26. 26.
    Cam D, Berk AT, Micili SC et al (2016) Histological and Immunohistochemical retinal changes following the intravitreal injection of Aflibercept, bevacizumab, and Ranibizumab in newborn rabbits. Curr Eye Res 17:1–8Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of OphthalmologyAdana City Training and Research HospitalAdanaTurkey
  2. 2.Adana Şehir HastanesiAdanaTurkey

Personalised recommendations